vTv Therapeutics (VTVT) EPS (Weighted Average and Diluted) (2020 - 2026)
vTv Therapeutics recorded quarterly EPS (Weighted Average and Diluted) of $1.65 in Q1 2026, up 512.5% quarter-over-quarter from -$0.4 in Q4 2025, and up 314.29% year-over-year from $0.4 in Q1 2025.
vTv Therapeutics' EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at $1.65 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 314.29% year-over-year to $1.65; the TTM figure through Mar 2026 stood at -$0.75 (up 74.66% YoY), while the FY2025 annual figure was -$3.2, changed 0.0% from the prior year.
- EPS (Weighted Average and Diluted) came in at $1.65 for Q1 2026 at vTv Therapeutics, up from -$0.4 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.65 in Q1 2026 to a low of -$9.78 in Q4 2022.
- A 5-year average of -$1.44 and a median of -$0.88 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) tumbled 6625.0% in 2023 and soared 314.29% in 2026, its largest moves.
- vTv Therapeutics' EPS (Weighted Average and Diluted) stood at -$9.78 in 2022, then soared by 82.92% to -$1.67 in 2023, then soared by 70.06% to -$0.5 in 2024, then rose by 20.0% to -$0.4 in 2025, then surged by 512.5% to $1.65 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered $1.65, -$0.4, and -$1.08 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | vTv Therapeutics | 413.85 Mn | 413.85 Mn | - | 1.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.65 |
| Dec 31, 2025 | -0.40 |
| Sep 30, 2025 | -1.08 |
| Jun 30, 2025 | -0.92 |
| Mar 31, 2025 | -0.77 |
| Dec 31, 2024 | -0.50 |
| Sep 30, 2024 | -0.88 |
| Jun 30, 2024 | -0.81 |
| Mar 31, 2024 | -1.17 |
| Dec 31, 2023 | -1.67 |
| Sep 30, 2023 | -3.19 |
| Jun 30, 2023 | -2.69 |
| Mar 31, 2023 | -2.16 |
| Dec 31, 2022 | -9.78 |
| Sep 30, 2022 | -0.05 |
| Jun 30, 2022 | -0.04 |
| Mar 31, 2022 | -0.10 |
| Dec 31, 2021 | -8.19 |
| Sep 30, 2021 | -0.02 |
| Jun 30, 2021 | -0.01 |
| Dec 31, 2020 | 0.03 |